ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2021
Validation of Risk Prediction Models to Inform Clinical Decisions After Acute Kidney Injury.
Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Examining variations in adherence to guideline-recommended post-acute kidney injury care in primary care in England: a population-based cohort study.BMC medicine · 2026Article
- Using health systems evidence to study and predict long-term outcomes of childhood acute kidney injury.Pediatric nephrology (Berlin, Germany) · 2026Article
- Systematic Review and Meta-Analysis of Machine Learning Models for Acute Kidney Injury Risk Classification.Journal of the American Society of Nephrology : JASN · 2025Article
- State of the art: Renal recovery after AKI - from basic science to clinical practice.Intensive care medicine · 2025Review
- Postoperative mid-to-long-term adverse event prediction model for patients receiving non-cardiac surgery: An extension of the Simple Postoperative AKI RisK (SPARK) model.Clinical kidney journal · 2025Article
- Biomarker Panels for Predicting Progression of Kidney Disease in Acute Kidney Injury Survivors.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Acute Kidney Injury Provider and Survivor Education: Current and Emerging Tools.Advances in kidney disease and health · 2025Review
- Nephrologist's Perceptions of Risk of Severe Chronic Kidney Disease and Outpatient Follow-up After Hospitalization With AKI: Multinational Randomized Survey Study.Canadian journal of kidney health and disease · 2025Article
- Predicting the risks of kidney failure and death in adults with moderate to severe chronic kidney disease: multinational, longitudinal, population based, cohort study.BMJ (Clinical research ed.) · 2024Article
- Recovery of kidney function after acute kidney disease-a multi-cohort analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Article
- Research Progress of Pyroptosis in Renal Diseases.Current medicinal chemistry · 2024Review
- Expectation of clinical decision support systems: a survey study among nephrologist end-users.BMC medical informatics and decision making · 2023Article
- Transitions of dialysis status and outcomes after the unplanned first dialysis: a nationwide population-based cohort study.Scientific reports · 2023Article
- Risk of de novo proteinuria following hospitalization with acute kidney injury.BMC nephrology · 2023Article
- A clarion call for follow-up of acute kidney injury survivors: perspective from a developing country.Journal of nephrology · 2022Article
- Early Comprehensive Kidney Care in Dialysis-Requiring Acute Kidney Injury Survivors: A Populational Study.Frontiers in medicine · 2022Article
- Cost-effectiveness and value of information analysis of NephroCheck and NGAL tests compared to standard care for the diagnosis of acute kidney injury.BMC nephrology · 2021Article
- Catechins: Therapeutic Perspectives in COVID-19-Associated Acute Kidney Injury.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
RATIONALE &
objectiveThere is limited evidence to guide follow-up after acute kidney injury (AKI). Knowledge gaps include which patients to prioritize, at what time point, and for mitigation of which outcomes. In this study, we sought to compare the net benefit of risk model-based clinical decisions following AKI. STUDY
designExternal validation of 2 risk models of AKI outcomes: the Grampian -Aberdeen (United Kingdom) AKI readmissions model and the Alberta (Canada) kidney disease risk model of chronic kidney disease (CKD) glomerular (G) filtration rate categories 4 and 5 (CKD G4 and G5). Process mining to delineate existing care pathways. SETTING &
participantsValidation was based on data from adult hospital survivors of AKI from Grampian, 2011-2013. PREDICTORS: KDIGO-based measures of AKI severity and comorbidities specified in the original models. OUTCOMES: Death or readmission within 90 days for all hospital survivors. Progression to new CKD G4-G5 for patients surviving at least 90 days after AKI. ANALYTICAL APPROACH: Decision curve analysis to assess the "net benefit" of use of risk models to guide clinical care compared to alternative approaches (eg, prioritizing all AKI, severe AKI, or only those without kidney recovery).
results26,575 of 105,461 hospital survivors in Grampian (mean age, 60.9 ± 19.8 [SD] years) were included for validation of the death or readmission model, and 9,382 patients (mean age, 60.9 ± 19.8 years) for the CKD G4-G5 model. Both models discriminated well (area under the curve [AUC], 0.77 and 0.86, respectively). Decision curve analysis showed greater net benefit for follow up of all AKI than only severe AKI in most cases. Both original and refitted models provided net benefit superior to any other decision strategy. In process mining of all hospital discharges, 41% of readmissions and deaths occurred among people recovering after AKI. 1,464 of 3,776 people (39%) readmitted after AKI had received no intervening monitoring. LIMITATIONS: Both original models overstated risks, indicating a need for regular updating.
conclusionsFollow up after AKI has potential net benefit for preempting readmissions, death, and subsequent CKD progression. Decisions could be improved by using risk models and by focusing on AKI across a full spectrum of severity. The current lack of monitoring among many with poor outcomes indicates possible opportunities for implementation of decision support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.